• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    2/9/23 11:06:35 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    SC 13G/A 1 p23-0704sc13ga.htm ROYALTY PHARMA PLC

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Royalty Pharma plc

    (Name of Issuer)
     

    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    G7709Q104

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G7709Q10413G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. G7709Q10413G/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. G7709Q10413G/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 7 of 10 Pages

     

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Royalty Pharma plc (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive offices are located at 110 East 59th Street, New York, New York 10022.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Partners, L.P., a Delaware limited partnership ("ACP") with respect to the Class A Ordinary Shares directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), as general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), as managing member of ACPGP, general partner of ACP, with respect to the Class A Ordinary Shares directly owned by ACP;
       
      (iv) Robert Atchinson ("Mr. Atchinson"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP; and
       
      (v) Phillip Gross ("Mr. Gross"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

     

    CUSIP No. G7709Q10413G/APage 8 of 10 Pages

     

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Class A Ordinary Shares, par value $0.0001 per share (the "Class A Ordinary Shares").

     

    Item 2(e). CUSIP NUMBER
      G7709Q104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  7,000,000
        (b) Percent of class:  1.59%.  The percentage set forth in this Schedule 13G/A is calculated based upon a total of 441,104,204 Class A Ordinary Shares outstanding as of November 4, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission on November 8, 2022.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote: 7,000,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  7,000,000

     

     

    CUSIP No. G7709Q10413G/APage 9 of 10 Pages

     

    ACP has the power to dispose of and the power to vote the Class A Ordinary Shares beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP's operations. Neither ACPGP nor ACA directly own any Class A Ordinary Shares.  By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the "Act"), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  7,000,000
        (b) Percent of class:  1.59%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  7,000,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  7,000,000

     

    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the Class A Ordinary Shares beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any Class A Ordinary Shares.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the Class A Ordinary Shares beneficially owned by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. G7709Q10413G/APage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
       
    DATE:  February 9, 2023  
       
    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL ADVISORS, L.L.C.  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ROBERT ATCHINSON  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    PHILLIP GROSS  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $RPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Norden Gregory sold $1,213,749 worth of Class A Ordinary Shares (33,500 units at $36.23) and converted options into 144,660 units of Class A Ordinary Shares, increasing direct ownership by 133% to 194,848 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/11/25 4:35:58 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, Chairman of the Board Legorreta Pablo G. was granted 21,901 units of Class A Ordinary Shares, increasing direct ownership by 2% to 904,396 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 5:00:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Coyne Terrance P. was granted 3,696 units of Class A Ordinary Shares (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 4:58:17 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma downgraded by UBS with a new price target

    UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

    6/3/24 9:17:33 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Royalty Pharma with a new price target

    UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

    6/14/22 7:27:46 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc

    SCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)

    8/14/25 8:30:21 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    8/13/25 4:33:18 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Royalty Pharma plc

    SCHEDULE 13G - Royalty Pharma plc (0001802768) (Subject)

    8/13/25 12:49:42 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

    On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform valueInvestments since 2020 on track to deliver mid-teens unlevered IRR, ahead of targetAchieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019Royalty market continues to grow rapidly, doubling over five years since Royalty Pharma's 2020 IPOStrong industry tailwinds and demand for royalty funding supported by Deloitte market study report NEW YORK, Sept. 11, 2025 (GLOBE NEWS

    9/11/25 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

    First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma's diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma roy

    9/10/25 7:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

    NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals a

    9/4/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

    Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr

    7/17/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

    4/8/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

    NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

    7/24/24 8:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    11/8/24 3:15:49 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

    SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

    7/29/24 4:30:11 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    2/13/24 10:17:30 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

    First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma's diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma roy

    9/10/25 7:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

    NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $600 million of 4.450% Notes due 2031 (the "2031 Notes");$900 million of 5.200% Notes due 2035 (the "2035 Notes"); and$500 million of 5.950% Notes due 2055 (the "2055 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025, subject to the satisfaction of customary closing conditions. Royalty Pharma intends to use the net proceeds from the

    9/2/25 8:30:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care